Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(1.07) by 86.92 percent. This is a 90.85 percent increase over losses of $(1.53) per share from the same period last year. The company reported quarterly sales of $0.100 which missed the analyst consensus estimate of $18.243 million by 100.00 percent. This is a 100.00 percent decrease over sales of $965.000 thousand the same period last year.